Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.

Jun SatoToshio ShimizuTakafumi KoyamaSatoru IwasaAkihiko ShimomuraShunsuke KondoShigehisa Kitano Kan Yonemori Yutaka FujiwaraKenji TamuraTakuya SuzukiTakao TakaseReiko NagaiKohei YamaguchiTaro SembaZi-Ming ZhaoMin RenNoboru Yamamoto

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

E7389-LF was well tolerated at 2.0 mg/m2 Q3W and 1.5 mg/m2 Q2W. Considering the toxicity profile of both regimens, the recommended dose was 2.0 mg/m2 Q3W. Expansion cohorts are ongoing.

Keyphrases

open label
oxidative stress
phase ii
clinical trial
randomized controlled trial
metastatic breast cancer
machine learning
double blind
placebo controlled
study protocol